Fusion Pharmaceuticals Inc Ordinary Shares FUSN
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if FUSN is a good fit for your portfolio.
News
-
Fusion Pharmaceuticals Mails Circular for Special Meeting of Shareholders and Announces Receipt of Interim Order
-
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CHRD, AA, FUSN, LABP
-
TAKE ACTION: The M&A Class Action Firm Launches Legal Inquiry for the Merger - ALPN, LABP, SWAV, FUSN
-
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates HMST, CHX, FUSN, DRQ
-
Kuehn Law Encourages HMST, CHX, FUSN, and DRQ Investors to Contact Law Firm
-
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates FUSN, LABP, JBT
-
STOCKHOLDER ALERT: The M&A Class Action Firm Continues Investigating the Merger – DOMA, LABP, FUSN, CBNK
-
Fusion Pharmaceuticals Announces Presentation of Interim Data from the Phase 2 TATCIST Clinical Trial Evaluating FPI-2265 at the AACR Annual Meeting 2024
Trading Information
- Previous Close Price
- $21.40
- Day Range
- $21.35–21.44
- 52-Week Range
- $2.31–21.55
- Bid/Ask
- $21.31 / $21.42
- Market Cap
- $1.82 Bil
- Volume/Avg
- 367,768 / 2.2 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 676.42
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Fusion Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The Company’s focus is on the development of next-generation radiopharmaceuticals as precision medicines for hard-to-treat cancers. It develops Targeted Alpha Therapies (TAT) together with its proprietary Fast-Clear linker technology. The firm's lead product candidate comprises FPI-1434, a monotherapy for the treatment of a variety of cancers; FPI-1966, for the treatment of head and neck and bladder cancers; and FPI-2059 among others.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 106
- Website
- https://www.fusionpharma.com
Comparables
Valuation
|
Metric
|
FUSN
|
CLDX
|
TYRA
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 7.64 | 4.82 | 3.45 |
Price/Sales | 676.42 | 260.58 | — |
Price/Cash Flow | — | — | — |
Price/Earnings
FUSN
CLDX
TYRA
Financial Strength
|
Metric
|
FUSN
|
CLDX
|
TYRA
|
|---|---|---|---|
Quick Ratio | 14.66 | 13.69 | 13.27 |
Current Ratio | 15.01 | 13.87 | 13.80 |
Interest Coverage | −19.06 | — | — |
Quick Ratio
FUSN
CLDX
TYRA
Profitability
|
Metric
|
FUSN
|
CLDX
|
TYRA
|
|---|---|---|---|
Return on Assets (Normalized) | −33.14% | −30.49% | −22.50% |
Return on Equity (Normalized) | −43.87% | −33.19% | −23.73% |
Return on Invested Capital (Normalized) | −36.42% | −32.85% | −27.79% |
Return on Assets
FUSN
CLDX
TYRA
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Pswrlfbyhq | Nypnx | $562.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Xpjmfzhz | Ckjqtf | $103.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Qwhsmrjky | Ylhhbg | $99.5 Bil | |
MRNA
| Moderna Inc | Ldfbjrql | Trltd | $38.8 Bil | |
ARGX
| argenx SE ADR | Kjljcvsq | Yvlv | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Hxwllqmm | Ffkf | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Bhqmcwdc | Yfypcn | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Qqmqcgytn | Zxvnwz | $17.3 Bil | |
RPRX
| Royalty Pharma PLC Class A | Tjwrqynn | Qyygjcq | $12.5 Bil | |
INCY
| Incyte Corp | Gdzrtvdb | Dbyqqm | $11.6 Bil |